1 KENDALL SQ STE B1101 CAMBRIDGE, MA 02139 Get Directions
1 KENDALL SQ STE B1101 CAMBRIDGE, MA 02139 Get Directions
Inspiration Biopharmaceuticals, Inc. was founded in 2004 by two dedicated fathers of children with hemophilia. Its focus is to revolutionize treatment of hemophilia through production of lower cost versions of existing intravenous recombinant therapies and development of non-invasive applications to enhance prophylactic administration.
It is estimated that only 25% of hemophilia patients worldwide receive treatment. Today, the average cost of hemophilia therapy for an adult has risen to nearly $200, 000 per year while the average annual cost for a child exceeds $100, 000.
Current therapies for the treatment of hemophilia are expensive to produce and are only effective when injected intravenously. It is anticipated that Inspiration's proprietary protein manufacturing technology will produce greater yields of high-quality product at lower cost compared with existing processes, and that these savings will ultimately be passed on to hemophilia patients and their families. Inspiration believes that reducing the cost of hemophilia therapy will have a significant impact on an individual's healthcare choices, career choices and financial stability.
The company's first product candidate is to be a less costly intravenous presentation of recombinant Factor IX. The proposed second generation product is a non-injectable recombinant Factor IX, designed specifically for prophylactic therapy. It is Inspiration's goal that, in the next decade, both products provide greater access to treatment and improve the quality of life for an increased number of hemophilia patients.
© Dun & Bradstreet, Inc. 2024. All rights reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.